-0.84 %
+0.43 %
+17.27 %
-21.33 %
-7.45 %
+35.83 %
+7.89 %
-29.10 %
-81.25 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
50.04M EUR
Turnover
14.69K EUR
P/E (adj.) (26e)
-15.33
EV/EBIT (adj.) (26e)
-13.64
P/B (26e)
6.44
EV/S (26e)
5,580.3
Dividend yield-% (26e)
-
